Prediction models of bronchopulmonary dysplasia: a systematic review and meta-analysis with validation

Author

T'ng Chang Kwok^{1,2}, Natalie Batey², Ka Ling Luu³, Andrew Prayle^{1,4}, Don Sharkey^{1,2}

Affiliation

- 1. Centre for Perinatal Research, School of Medicine, University of Nottingham, E floor, East Block, Queen's Medical Centre, Nottingham, NG7 2UH.
- 2. Nottingham Neonatal Service, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH.
- 3. Nottingham Maternity Service, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH.
- 4. NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, C Floor, South Block, Derby Road, Nottingham, NG7 2UH.

Corresponding Author

Don Sharkey, Centre for Perinatal Research, School of Medicine, University of Nottingham, E floor, East Block, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom.

Email: Don.sharkey@nottingham.ac.uk

Keywords

Bronchopulmonary dysplasia, prediction model, preterm infant

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

What is the key question?

This review aims to provide a comprehensive assessment of all BPD prediction

models developed to address the clinical uncertainty of which predictive model is

sufficiently valid and generalisable for use in clinical practice and research.

What is the bottom line?

Published BPD prediction models are mostly outdated, single centre and lack

external validation.

Why read on?

Laughon's 2011 model is the most promising but more robust models, using

contemporary data with external validation are needed to support better treatments.

Total words: 3,452 words

Total number of figures and tables: 3 figures 2 tables

Abstract

Introduction

Neonatal bronchopulmonary dysplasia (BPD) is associated with lifelong respiratory and neurological sequalae. Prediction models could identify infants at greatest risk of BPD and allow targeted preventative strategies. We performed a systematic review and meta-analysis with external validation of identified models.

Methods

Studies using predictors available before day 14 of life to predict BPD in very preterm infants were included. Two reviewers assessed 7,628 studies for eligibility. Meta-analysis of externally validated models was followed by validation using 62,864 very preterm infants in England and Wales.

Results

64 studies using 53 prediction models were included totalling 274,407 infants (range 32–156,587/study). 35 (55%) studies predated 2010; 39 (61%) were single-centre studies. 46 (87%) models were developed for the first week of life. Overall, 97% of studies had a high risk of bias, especially in the analysis domain. Internal (25%) and external (30%) validation were performed infrequently in the 44 model derivation studies. Following meta-analysis of 22 BPD and 11 BPD/death composite models, Laughon's day one model was the most promising in predicting BPD and death with a fair C-statistic of 0.76 (95% CI 0.70–0.81) and good calibration. Six models were

externally validated in our cohort with a C-statistic between 0.70 to 0.90 but with poor calibration.

Conclusion

Few BPD prediction models were developed with contemporary populations, underwent external validation, or had calibration and impact analyses. To reduce the adverse impact of BPD, we need contemporary, validated, and dynamic prediction models to allow targeted preventative strategies.

Introduction

Bronchopulmonary dysplasia (BPD), one of the most common and complex neonatal conditions¹, continues to increase and affects approximately 28,000 and 18,000 babies annually in Europe² and the US³ respectively. Preterm infants with BPD have significant long-term respiratory and neurodevelopmental complications into adulthood⁴, including abnormal lung function⁵ and poor school performance⁴.

There are a myriad of trials with at least 24 Cochrane reviews looking at BPD preventative interventions, including postnatal corticosteroids. However, their benefit in preventing BPD may not outweigh the significant side effects, including gastrointestinal perforation and neurodevelopmental impairment⁶⁷. This demonstrates the complexity in BPD management in balancing the risk of significant long-term morbidity from BPD with that of exposure to potentially harmful treatments⁸.

BPD prediction models aim to provide a personalised risk approach in identifying high-risk very preterm infants for timely preventative treatments. Despite numerous models being developed, none are used routinely in clinical practice. This review aims to provide a comprehensive assessment of all BPD prediction models developed to address the clinical uncertainty of which predictive model is sufficiently valid and generalisable for clinical and research use. Secondly, we will validate eligible models in a large national contemporaneous cohort of very preterm infants.

Material and Methods

Systematic Review

There was no deviation from the protocol published in PROSPERO⁹. Standard Cochrane Neonatal and Prognosis Methods Group methodology were used.

Inclusion criteria

Cohort, case-control, and randomised controlled trials used in developing or validating the prediction models were included. Very preterm infants born before 32 weeks of gestational age (GA) and less than two weeks old at the time of BPD prediction were included. This ensures the clinical applicability and timeliness of the prediction models to support clinical decision making on preventative treatments. Studies that used non-universally accessible predictors such as pulmonary function tests, ultrasonography and biomarkers were excluded. BPD was defined as a respiratory support requirement at either 28 days of age or 36 weeks of corrected gestational age (CGA)¹⁰. The composite outcome of BPD and death before discharge was included as a secondary outcome.

Search methods

Standard Cochrane Neonatal¹¹ and prognostic study search filters¹² were used.

"Bronchopulmonary dysplasia OR BPD OR chronic lung disease OR CLD" search terms were used to search the CENTRAL, Ovid MEDLINE, CINAHL, EMBASE and Scopus databases until 13/08/2021 (**Appendix 1**).

Data collection

Two reviewers (TK, NB or KL) independently screened the title and abstract as well as full-text reports for inclusion before independently extracting data and assessing the risk of bias using the PROBAST tool¹³ (**Appendix 2**). These were done using a web-based tool CADIMA¹⁴. Any disagreement was resolved by discussion.

Prediction model performance measure

Discrimination (C-statistics), calibration (Observed:Expected ratio (O:E ratio)) and classification (net benefit analysis) measures were extracted alongside their uncertainties.

Missing data

Study authors were contacted to obtain any missing data. Failing that, missing performance measure were approximated using the methodology proposed by Debray et al.¹⁵ and R statistical package "metamisc"¹⁶.

Meta-analysis

Meta-analysis of the performance measures, using the random-effects approach and R statistical package "metafor" was performed for externally validated models. Sensitivity analysis was performed by excluding studies with an overall high risk of bias. We pre-specified that we would assess the source of heterogeneity and reporting deficiencies if more than ten studies were included.

Conclusions

The adapted **G**rades of **R**ecommendation, **A**ssessment, **D**evelopment and **E**valuation (GRADE) framework¹⁹ was used to assess the certainty of the evidence.

External Validation of Eligible Models

Study design

A population-based retrospective cohort study from the UK National Neonatal Research Database (NNRD)²⁰ was used to externally validate BPD prediction models identified in the systematic review. We included all very preterm infants admitted to 185 neonatal units in England and Wales from January 2010 to December 2017. This encompasses over 90% of English neonatal units in 2010, with full coverage in England and Wales in 2012 and 2014 respectively. Infants with birthweight z score below -4 or above 4 were excluded as they were likely erroneous entries. Further details of the data items extracted are found within the National Neonatal Dataset[29] and **Appendix 3**. Ethical approval was granted by the Sheffield Research Ethics Committee (REC reference 19/YH/0115).

Statistical analysis

Data extraction and statistical analysis were done using STATA/SE version 16 (StataCorp) and R version 4 (R Core Team). Summary statistics (median, interquartile range (IQR) and percentages) were used to describe the data. Missing data was imputed five times using Multivariate Imputation by Chained Equations²¹.

Model performances were assessed in three domains: discrimination (C-statistics), calibration (calibration plot and O:E ratio) and utility measure (decision curve analysis).

Results

Systematic review

Literature search

Of the 7,628 potentially eligible studies identified, 194 full-text articles were screened with 122 articles excluded as studies identified risk factors rather than developing prediction models (48%), predictors available after two weeks of age (24%), infants above 32 weeks GA at birth (17%), non-universally accessible predictors (10%) or wrong outcome measure reported (2%). Data were extracted from the 72 full-text articles (**Appendix 4**), encompassing 64 studies and 53 BPD prediction models (**Figure 1**).

Description of included studies

Of the 64 included studies, 31 were BPD prediction model development studies, 20 were validation studies, and 13 were development and external validation studies. Fifty-five of the studies were cohort studies; five were randomised controlled trials; two used a combination of randomised control trials and cohort studies with one case-control study and another with unreported study design. Twenty-six studies were performed in North America, fourteen in Europe, thirteen in Asia, five in South America and Australia/New Zealand each and one study was carried out worldwide.

Twenty studies developed and validated BPD prediction models based on infants born before 2000, with a further 15 studies using infants born between 2000 to 2010. The 64 included studies recruited 274,407 (range 32 and 156,587) infants, with the majority (50 studies) recruited less than 1,000 infants. 39 (61%) studies were conducted in single centre. Forty-seven studies used BPD as their outcome, while 14 studies used a BPD/death composite outcome, with three further studies reporting both BPD and BPD/death composite outcomes. Thirty-one studies defined BPD at 36 weeks CGA, while 22 studies used the timepoint of 28 days old. Six studies defined BPD using both timepoints. Five studies did not report how BPD was defined (Table 1).

Study	Country / Region	Number of centres	Data collection period	Study design	Number of infants	Number of BPD	Number of deaths	Gestation	Birthweight (grams)	Outcome
Development only										
Cohen 1983	USA	1	1978 – 1981	Cohort	69	42	NR	NR	NR	BPD 28d
Palta 1990	USA	5	NR	Cohort	42	36	NR	NR	1042 ± 267	BPD 30d
Parker 1992	USA	1	1976 – 1985 (D) 1986 – 1990 (V)	Cohort	1500 (D) 875 (V)	252 (D) 288 (V)	328 (D) 139 (V)	29.6 ± 2.6 (D) 28.7 ± 2.9 (V)	1113 ± 261 (D) 1066 ± 278 (V)	BPD 28d & Death/BPD28d
Corcoran 1993	UK	1	1980 – 1990	Cohort	412	140	115	29.7±2.8	1345 ± 445	BPD 28d
Gortner 1996	Germany	1	1985 – 1992	Case – control	152	76	48	29.2 ± 2.0	1139 ± 249	BPD 28d
Ryan 1996	UK	1	1991 – 1992 (D) 1993 (V)	Cohort	204 (D) 47 (V)	8FD 28d 85 (D) NR (V) BPD 36w 51 (D) NR (V)	7 (D) NR (V)	27.5 ± 1.5 (D) NR (V)	1283 ± 327 (D) NR (V)	BPD 28d & BPI 36w
Groves 2004	NZ	1	1998 – 2000	Cohort	290	60	54	27.9 ± 8.4	863 ± 626	Death/BPD 36v BPD 28d BPD 28d
Cunha 2005	Brazil	1	2000 – 2002	Cohort	86	45	NR	29.0 ± 2.3	1029 ± 222	BPD 28d
Choi 2006	Korea	1	2000 - 2005	Cohort	81	48	NR	28.1 ± 1.7	1051 ± 233	BPD 28d
Henderson-Smart 2006	Australia / NZ	25	1998 – 1999 (D) 2000 – 2001 (V)	Cohort	5599 (D) 5854 (V)	1235 (D) 1475 (V)	NR	28.7 ± 2.2 (D) 28.7 ± 2.2 (V)	1233 ± 404 (D) 1235 ± 408 (V)	BPD 28d BPD 28d BPD 36w Death/BPD 36v
Ambalavanan 2008	USA	16	2001 – 2003	RCT	420	151	202	26.0 ± 2.0	839 ± 262	Death/BPD 36v
Gottipati 2012	USA	1	2002 - 2007	Cohort	417	NR	NR	NR	NR	BPD (NR) BPD (NR) Death/BPD 36v BPD 28d
Roth-Kleiner 2012	Switzerland	1	1998 – 2007	Cohort	936	NR	NR	NR	NR	BPD (NR)
Chock 2014	USA	1	2006 - 2010	Cohort	187	73	12	27.6 ± 2.0	1005 ± 260	Death/BPD 36v
Yang 2014	Korea	1	2003 - 2010	Cohort	261	66	0	30.6 ± 2.4	1549 ± 487	BPD 28d
Ochab 2016	Poland	1	NR	NR	109	46	NR	NR	NR	BPD 28d
Wai 2016	USA	25	2010 - 2013	RCT	495	283	53	25.2 ± 1.2	700 ± 165	Death/BPD 36v
Kim 2017	Korea	1	2008 – 2014	Cohort	304	110	13	28.3 ± 2.3	1032 ± 276	Death/BPD 36v
Beltempo 2018	Canada USA /	30	2010 – 2015	Cohort	9240	2959	1277	26.7	925 ± 251	BPD 36w
Boghossian 2018	Puerto Rico	852	2006 – 2014	Cohort	156587	NR	NR	NR	NR	BPD 36w
Hunt 2018	UK	1	2012 – 2017	Cohort	432	228	7	NR	NR	BPD 28d
Sullivan 2018	USA	2	2009 – 2015	Cohort	778	186	48	28.0 ± 2.8	1029 ± 298	BPD 36w
Fairchild 2019	USA	1	2009 – 2014	Cohort	502	172	15	27.3 ± 3.0	1023 ± 335	BPD 36w
Sun 2019	China	1	2015 – 2018	Cohort	296	144	0	29.9 ± 1.6	1417 ± 328	BPD 28d
Valenzuela-Stutman 2019	South America	15	2001 – 2015	Cohort	16407	2580	3938	29 ± 2.9	1099 ± 275	BPD 36w & Death/BPD 36v

Study	Country / Region	Number of centres	Data collection period	Study design	Number of infants	Number of BPD	Number of deaths	Gestation	Birthweight (grams)	Outcome
Dylag 2020	USA	6	2011 – 2014	Cohort	704	BPD 28d 414 BPD 36w 276	0	26.7 ± 1.4	922 ± 229	BPD 28d
Shah 2020	USA	1	2006 – 2016	Cohort	730	343	139	27 ± 2	867 ± 198	Death/BPD 36w
Sharma 2020	USA	1	2011 – 2017	Cohort	263	155	16	25.2 ± 1.4	805 ± 195	BPD 36w
Vaid 2020	USA	1	2005 – 2018	Cohort	1832	NR	NR	NR	NR	BPD (NR)
Shim 2021	Korea	66	2013 – 2016 (D) 2017 – 2017 (V)	Cohort	4600 (D) 1740 (V)	BPD 28d 2583 (D) 1003 (V) BPD 36w 1370 (D) 463 (V)	1053 (D) 280 (V)	28.7 ± 2.6 (D) 28.8 ± 2.6 (V)	1119 ± 264 (D) 1127 ± 260 (V)	BPD 28d & BPI 36w
Ushida 2021	Japan	200	2006 – 2015	Cohort	31157	7504	1958	27.8 ± 2.5	973 ± 299	BPD 36w
<u>Development and val</u> Ryan 1994	ilidation UK	2	1988 – 1989	Cohort	166 (D) 133 (V)	47 (D) 59 (V)	NR	29 ± 2.6 (D) 30 ± 3.1 (V)	1043 ± 189 (D) 1056 ± 177 (V)	BPD 28d
Rozycki 1996	USA	1	1987 – 1989 (D) 1990 – 1991 (V)	Cohort	14d model 116 (D) 61 (V) 8h model 698 (D)	14d model 38 (D) 34 (V) 8h model 44 (D)	NR	14d model 26.7 ± 2.0 (D) NR(V) 8h mode 29.7 ± 2.2 (D)	14d model 911 ± 227 (D) NR(V) 8h model 1352 ± 478 (D)	BPD 28d
Romagnoli 1998	Italy	1	1989 – 1991 (D) 1993 – 1996 (V)	Cohort	50 (D) 149 (V)	28 (D) 82 (V)	NR	28.4 ± 2.1 (D) 28.7 ± 2.4 (V)	893 ± 206 (D) 931 ± 208 (V)	BPD 28d Death/BPD 36v
Yoder 1999	USA	1 (D) 3 (V)	1990 – 1992 (D) 1993 – 1995 (V)	Cohort	48 (D) 110 (V)	15 (D) 33 (V)	NR	27.0 ± 2.0 (D) 26.5 ± 2.1 (V)	897 ± 243 (D) 905 ± 222 (V)	Death/BPD 36v
Chien 2002	Canada	17	1996 – 1997	Cohort	4226	NR	NR	29.0 ± 2.0	1390 ± 457	BPD 36w
Kim 2005	Korea	1	1997 – 1999 (D) 2000 – 2001 (V)	Cohort	197 (D) 107 (V)	30 (D) 9 (V)	34 (D) 11 (V)	28.2 ± 1.9 (D) 28.5 ± 1.9 (V)	1043 ± 263 (D) 1095 ± 270 (V)	BPD 36w
Bhering 2007	Brazil	1	1998 – 2003 (D) 2003 – 2005 (V)	Cohort	247 (D) 61 (V)	68 (D) NR (V)	5 (D) NR (V)	29.1 ± 2.4 (D) NR (V)	1083 ± 237 (D) NR (V)	BPD 28d
May 2007	UK	1	1995 – 1998 (D) 2004 – 2005 (V)	RCT (D) Cohort (V)	136 (D) 75 (V)	BPD 28d 82 (D) 32 (V) BPD 36w 38 (D) 22 (V)	NR	27.7 ± 2.0 (D) 29.3 ± 2.6 (V)	1017 ± 246 (D) 1245 ± 424 (V)	BPD 28d & BPI 36w

Study	Country / Region	Number of centres	Data collection period	Study design	Number of infants	Number of BPD	Number of deaths	Gestation	Birthweight (grams)	Outcome
Laughon 2011	USA	17	2000 – 2004	RCT	3629 (D) 1777 (V)	1943 (D) 1215 (V)	468 (D) 210 (V)	26.7 ± 1.9 (D) 25.7 ± 1.1 (V)	897 ± 203 (D) 830 ± 175 (V)	Death/BPD 28c
Gursoy 2014	Turkey	1	2006 – 2009 (D) 2012 (V)	Cohort	652 (D) 172 (V)	150 (D) 54 (V)	NR	29.4 ± 1.9 (D) 28.9 ± 2.3 (V)	1218 ± 220 (D) 1102 ± 251 (V)	BPD 28d
Anand 2015	USA	2	NR	Cohort	49 (D) 46 (V)	16 (D) NR (V)	NR	NR	NR	BPD 28d
Mistry 2020	Australia	NR	NR	Cohort	NR	NR	NR	NR	NR	BPD (NR)
Baud 2021	France	21	2008 – 2014	RCT	523	125	107	26.4 ± 0.8	854 ± 170	Death/BPD 36v
Validation only						BPD 28d 75				BPD 28d & BPI
Fowlie 1998	UK	6	1988 – 1990	Cohort	398	BPD 36w 31	81	29.8 ± 2.5	1065 ± 186	36w
Hentschel 1998	Germany	1	1991 – 1993	Cohort	188	BPD 28d 61 BPD 36w 45	30	28.6 ± 0.3	1101 ± 281	BPD 28d & BPI 36w
Schroeder 1998	Germany	1	1985 – 1992	Cohort	103	59	NR	28.5 ± 1.9	1000 ± 153	BPD 28d
Srisuparp 2003	USA	1	1996 – 1997	Cohort	138	47	24	27.6 ± 2.4	995 ± 247	BPD 36w
Thowfique 2010	Singapore	1	2006 – 2007	Cohort	388	59	40	28.7 ± 3	1029 ± 251	BPD (NR)
Carvalho 2011	Brazil	2	2002 – 2009	Cohort	86	20	18	28.3 ± 1.8	851 ± 233	BPD 36w
Onland 2013	Worldwide	85	1986 – 2004	10 RCTs	3229	1094*	582*	27.3 ± 3.8	989 ± 315	BPD36w & Death/BPD 36v
Truog 2014	USA	1	2008 – 2010	Cohort	158	115	15	NR	NR	Death/BPD 36v
Sullivan 2016	USA	1	2004 – 2014	Cohort	566	98	51	28.6 ± 2.9	NR	BPD 36w
Ozcan 2017	Turkey	1	2011 – 2012	Cohort	246	28	32	29.2 ± 2.15	1323 ± 331	BPD 36w
Gulliver 2018	USA	1	2010 – 2016	Cohort	622	223	61	27.0 ± 1.9	963 ± 301	Death/BPD 36v
Vasquez 2018	Colombia	2	2010 – 2016	Cohort	335	68	NR	31 ± 1.5	1328 ± 328	BPD 28d
Jung 2019	Korea	1	2010 – 2014	Cohort	138	57	17	25.9 ± 1.3	780 ± 225	Death/BPD 36v BPD 28d Death/sev BPD 36w
Lee 2019	Korea	67	2013 – 2016	Cohort	6938	1916	957	28.3 ± 2.4	1059 ± 283	BPD 36w
Baker 2020	Australia	2	2016 – 2017	Cohort	187	72 (sev BPD)	18	26.6 ± 1.5	872 ± 178	Death/sev BPD 28d
Bhattacharjee 2020	USA	1	2012 – 2013	Cohort	69	31	5	24.75 ± 1.5	722 ± 160	Sev BPD 36w
Sotodate 2020	Japan	1	2010 – 2017	Cohort	171	74	19	25.5 ± 1.6	741.3 ± 208.2	BPD 36w
Steocklin 2020	Australia	1	2017 – 2018	Cohort	32	NR	NR	26.2 ± 1.0	NR	BPD 36w
Alonso 2021	Spain	1	2013 – 2020	Cohort	202	BPD 28d 58 BPD 36w 21	23	29.5 ± 2.1	1142 ± 256	BPD 28d & BPI 36w
Rysavy 2021	USA	14 (RCT) 32 (Cohort)	1996 – 1997 (RCT) 2016 – 2018 (Cohort)	RCT / Cohort	807 (RCT) 2370 (Cohort)	356 (RCT) 1417 death / BPD (Cohort)	114 (RCT) 1417 death / BPD (Cohort)	25.8 ± 1.8 (RCT) NR (Cohort)	770 ± 136 (RCT) NR (Cohort)	Death/BPD 36v

Table 1 Characteristics of 64 included studies. NR = Not reported. D = Derivation. V = Validation. RCT = Randomised controlled trials. Sev= Severe. * Data obtained from the original study protocol (Cools et al 2010²²).

70% of the 44 derivation studies used logistic regression to develop the BPD prediction tool, with 11% used univariate analysis; 5% used clinical consensus as well as a combination of logistic regression and classification and tree analysis (CART) respectively; and 2% used CART, gradient boosting, Bayesian network and a combination of logistic regression and support vector machine, respectively. Complete case analysis was used in 41% of the included derivation studies, while handling of missing data was not reported in the remaining 59%. Internal and external validation was done in 25% and 30% of the studies, respectively. Validation was not done in the remaining 45% of studies. 75% of the studies assessed discrimination using C-statistics. In contrast, only 16% of the studies evaluated calibration using the goodness of fit (five studies), calibration plot (1 study) and O:E ratio (1 study). Of the 44 models, ten (23%), eight (18%) and four (9%) models provided a formula, score chart and nomogram respectively. Only two (5%) models provided an online calculator (**Table 2**).

Of the 53 BPD prediction models identified, 19 used predictors available within 24 hours of age, while 20 and six models relied on predictors available between two to seven days and above seven days of age respectively. Seven models used predictors available at various timepoints while the timepoints were unavailable for one model. The BPD prediction models considered a median of 14 predictors before using a median of five predictors in the final models. The five most used predictors were GA, birthweight, the fraction of inspired oxygen (F_iO₂), gender and invasive ventilation requirement, which were used in 33%–69% of models (**Appendix 5**).

Study			Model Developme	ent	Model Validation			
Stady	Approach	Continuous	Missing value	Predictor selection	Presentation	Approach	Discrimination	Calibration
Cohen 1983	Clinical consensus	Categorical	Complete case	Clinical consensus	NR	Same cohort	NR	None
Palta 1990	Clinical consensus	Kept linear	NR	Clinical consensus	Formula	Same cohort	NR	None
Parker 1992	Regression	Kept linear	Complete case & Replace mean	Univariate → stepwise	Formula	Bootstrapping / Temporal (year)	NR	O:E ratio
Corcoran 1993	Regression	Categorical	Complete case	Univariate → stepwise	Formula	Random split	NR	None
Ryan 1994	Regression	Kept linear	NR	Univariate → stepwise	Formula	New dataset	ROC	None
Gortner 1996	Regression	Kept linear	NR	Univariate → stepwise	Formula	Same cohort	NR	None
Rozycki 1996	Regression	Categorical	Complete case	Univariate → stepwise	Nomogram	New dataset	NR	None
Ryan 1996	Regression	Kept linear	NR	Univariate → stepwise	Formula	Temporal (year)	ROC	None
Romagnoli 1998	Regression	Categorical	NR	Univariate analysis	Formula	New dataset	ROC	None
Yoder 1999	Regression	Categorical	NR	Univariate analysis	Score chart	New dataset	ROC	None
Chien 2002	Regression	Kept linear	Complete case	NR	NR	Same cohort	ROC	Goodness of fi
Groves 2004	Univariate analysis	Kept linear	NR	Stepwise selection	NR	Same cohort	ROC	None
Cunha 2005	Regression	Categorical	NR	Univariate → stepwise	Score chart	Same cohort	NR	None
Kim 2005	Regression	Categorical	Complete case	Univariate → stepwise	Score chart	New dataset	ROC	None
Choi 2006	Regression	Categorical	NR	Univariate → stepwise	Score chart	Same cohort	ROC	None Goodness of fi Goodness of fi None None None None None Goodness of fi
Henderson-Smart 2006	Regression	Categorical	Complete case	Univariate → stepwise	Formula	Temporal (year)	ROC	Goodness of fi
Bhering 2007	Regression	Categorical	Complete case	Stepwise selection	Score chart	New dataset	ROC	Goodness of fi
May 2007	Univariate analysis	Kept linear	NR	No selection	NR	New dataset	ROC	None
Ambalavanan 2008	Regression & CART	Kept linear	Complete case	Stepwise selection	Nomogram	Cross-validation	ROC	None
Laughon 2011	Regression	Kept linear	NR	Univariate → stepwise	Formula/Online tool	New dataset	ROC	None
Gottipati 2012	Regression	Kept linear	NR	NR .	Score chart	Same cohort	NR	None
Roth-Kleiner 2012	Regression	Categorical	NR	Stepwise selection	Score chart	Cross-validation	ROC	None
Chock 2014	Regression & CART	Kept linear	NR	NR	Nomogram	Same cohort	ROC	None
Gursoy 2014	Regression	Categorical	NR	Univariate → stepwise	Score chart	New dataset	ROC	Goodness of fi
Yang 2014	Univariate analysis	Kept linear	NR	No selection	NR	Same cohort	ROC	None
Anand 2015	Bayesian Network	Categorical	NR	NR	NR	New dataset	ROC	None
Ochab 2016	Regression & SVM	Kept linear	NR	Stepwise selection	NR	Cross-validation	NR	None
Wai 2016	Regression	Kept linear	Complete case	Univariate → stepwise	NR	Same cohort	ROC	None
Kim 2017	Regression	Kept linear	NR	Univariate analysis	NR	Same cohort	NR	None
Beltempo 2018	Regression	Categorical	Complete case	No selection	NR	Same cohort	ROC	None
Boghossian 2018	Regression	Categorical	NR	No selection	NR	Random split	ROC	None
Hunt 2018	Univariate analysis	Categorical	NR	No selection	NR	Same cohort	ROC	None
Sullivan 2018	Regression	Transformation	NR	No selection	NR	Bootstrapping	ROC	None
Fairchild 2019	Regression	Kept linear	NR	Stepwise selection	NR	Same cohort	ROC	None
Sun 2019	Univariate analysis	Kept linear	Complete case	No selection	NR	Same cohort	ROC	None
Valenzuela–Stutman 2019	Regression	Kept linear	NR	Stepwise selection	NR	Random split	ROC	None
Dylag 2020	Regression	Kept linear	Complete case	Stepwise selection	NR	Random split	ROC	None
Mistry 2020	Regression	Kept linear	NR	NR	NR	Same cohort	ROC	None
Shah 2020	Regression	Kept linear	Complete case	A priori knowledge	NR	Same cohort	ROC	None
Sharma 2020	CART	Kept linear	Complete case	CART	Nomogram	Same cohort	ROC	None
Vaid 2020	Gradient boosting	NR	Complete case	NR	NR	Cross-validation	ROC	None
Baud 2021	Regression	Kept linear	NR	Stepwise selection	Formula	Same cohort	ROC	Goodness of fi

Shi m 2021	Regression	Kept linear	Complete case	Stepwise selection	Formula	Temporal (year)	NR	None
Ushida 2021	Regression	Kept linear	Complete case	Stepwise selection	Formula/Online tool	Random split	ROC	Calibration

Table 2 Methodology used by the derivation studies. NR = Not reported. CART = Classification and regression tree. SVM = Support vector machine.

ROC = receiver operating characteristics curve. O:E ratio = Observed:expected ratio.

Risk of Bias

The majority of the studies were assessed to have a low risk of bias for the participants (84%), predictors (92%) and outcome (89%) domains. 60 (94%) studies were assessed to have a high risk of bias in the analysis domain based on the PROBAST tool¹³ due to various reasons including calibration not assessed (55 studies (86%)); small sample size (37 studies (58%)); inappropriate handling of missing data (21 studies (33%)); lack of internal/external validation (9 studies (14%)); inappropriate selection approach for predictors (6 studies (9%)); and inappropriate handling of continuous predictors (2 studies (3%)).

Twenty-one studies (33%) had high applicability concerns in the participant's domain as they targeted a specific group of very preterm infants, usually infants at a higher risk of BPD (for example, ventilated infants only in 17 studies (27%)). Although universally accessible, predictors used in ten studies (16%) may not be routinely collected. Eight studies (13%) used BPD definitions that deviated against current consensus¹⁰ (**Figure 2**, **Appendix 6**).

Discrimination

The C-statistics of the included prediction models ranged from 0.52–0.95 in the external validation studies with better performance in models using predictors beyond seven days of age. Meta-analysis could only be done on 22 (50%) and 11 (35%) models for BPD and BPD/death composite outcome respectively, as the remaining 22 and 20 models were only validated in one study. The C-statistics confidence interval (CI) were wide due to the small number of studies in each meta-

analysis. The five models with CI above 0.5 for BPD from the meta-analysis were CRIB I²³, CRIB II²⁴ as well as Valenzuela–Stutman 2019²⁵ (Birth, Day 3 and 14 models). Similarly, for the BPD/death composite, the five models with CI above 0.5 from the meta-analysis were Laughon 2011²⁶ (Day 1, 3, 7 and 14 models) and Valenzuela–Stutman 2019²⁵ (Day 14 model) (**Appendix 7**). Meta-analysis for the Valenzuela–Stutman 2019 models²⁵ could only be performed after including validation findings from our cohort study.

Calibration

The O:E ratio was reported in four external validation studies²⁷⁻³⁰ evaluating six prediction models (Rozycki 1996²⁷, Parker 1992²⁸ and Laughon 2011²⁶ (Day 1, 3, 7 and 14 models)) with considerable variation in the O:E ratio among the included models. Meta-analysis of the O:E ratio could only be done on one model (Laughon 2011²⁶ (Day 1)) with an O:E ratio of 0.96 (95% CI 0.85–0.99) (**Appendix 8**).

The calibration plot was reported in three studies²⁹⁻³¹, assessing six models (Palta 1990³², Sinkin 1990³³, Ryan 1996³⁴, Kim 2005³⁵ as well as Laughon 2011²⁶ (Day 1 and 3 models) (**Appendix 9**).

Classification

No studies reported net benefit or decision curve analyses.

Heterogeneity and reporting deficiencies

As there were less than ten validation studies in a meta-analysis, subgroup analysis and funnel plots were not performed. Sensitivity analysis was not performed as all studies had an overall high risk of bias except for two studies^{29 36}.

Summary of findings

Due to the lack of validation studies, a conclusion could only be made for one model Laughon 2011²⁶. There was moderate quality of evidence that the discrimination and calibration performances of the Laughon 2011²⁶ model in predicting the BPD/death composite outcome using predictors at day one of age with C-statistic of 0.76 (95% CI 0.70–0.81) and O:E ratio of 0.96 (95% CI 0.85–0.99). The evidence was downgraded by one level due to study limitation whereby there was variation in the BPD definition used, as well as some studies recruiting high-risk infants only (such as invasively ventilated infants) to validate the model.

External validation

Patient cohort

After exclusions (**Appendix 10**), 62,864 very preterm infants were included (**Appendix 11**). 17,775 (31%) infants developed BPD while 5,718 (9%) infants died before discharge from the neonatal unit.

20

Model performance

We were able to externally validate six prediction models (Henderson-Smart 2006³⁷, Valenzuela-Stutman 2019²⁵ (Dav1, 3 and 14 models). Shim 2021³⁸ and Ushida 2021³⁹) in our retrospective cohort. The variables in the remaining models were not available in our cohort. The discrimination (C-statistics) and calibration (O:E ratio and calibration plot) (Figure 3) performances were variable among the models. Although the models displayed fair to good discrimination with C-statistics of 0.70–0.90, they had poor calibration as indicated by the calibration plot and O:E ratio between 0.39-2.31. The Valenzuela-Stutman 2019 models²⁵ appear to overestimate the predicted risk, whereas the remaining three models (Henderson-Smart 2006³⁷. Shim 2021³⁸ and Ushida 2021³⁹) tend to underestimate the predicted risk. Of the six externally validated models, four models (Henderson-Smart 2006³⁷, Valenzuela–Stutman 2019²⁵ (Day 14 models), Shim 2021³⁸ and Ushida 2021³⁹) indicated superior net benefit across a reasonable range of threshold probabilities of 30% to 60% in deciding postnatal corticosteroid treatment in the decision curve analysis (Appendix 12). The threshold probabilities used were identified in a meta-regression of 20 randomised controlled trials8.

Discussion

Our study is an update to the systematic review carried out nearly a decade ago³¹, with a further 27 prediction models identified since the last review. Our systematic review identified 64 studies that developed and/or validated 53 BPD prediction models with meta-analysis carried out on 22 models. Due to the lack of external validation studies, we could not identify a prediction model for routine clinical use. Further external validation, including assessment of both discrimination and

calibration performances in a population similar to that whereby the model will be used, is needed before any model could be adopted in clinical practice. However, the most promising prediction model that could be considered based on our meta-analysis was Laughon 2011²⁶ in predicting the BPD/death composite outcome using predictors at day one of age. Further re-calibration of the model based on the local population of interest, with re-assessment of its performance in subsequent external validation studies (if re-calibrated), may be needed before being used in clinical practice.

We have also externally validated six prediction models²⁵ ³⁷⁻³⁹ in our retrospective population-based cohort study. Although they have fair to good discrimination, they were not well calibrated in our cohort. To be useful, prediction tools need to be generalizable to current datasets highlighting the importance of external validation.

Implications for clinical practice and research

The implementation of BPD prediction models in clinical practice is limited by the lack of external validation of the published models. Less than a third of the identified prediction models were externally validated. Furthermore, half of the externally validated models were only validated by one study. This potentially limits the generalisability of the model performance to other infant populations.

Sample size

Most external validation studies had small sample sizes or were restricted to specific high-risk infant populations (for example, ventilated infants only). Furthermore, 61% of studies were single centre only. This potentially limits the generalisability of the models. It is recommended that prediction model development studies should have at least 20 infants with the outcome of interest for each candidate predictor, while validation studies should have at least 100 infants with the outcome¹³.

Missing values

The majority of the studies did not report missing data or excluded infants with missing data. A clear description of the handling of missing data should be provided. Complete case analysis should be avoided if possible¹³.

Variation in prediction timepoint and outcome definition

Nearly three-quarters of the included prediction models predicted BPD, the remainder predicting the BPD/death composite outcome. As death and BPD are semi-competitive risks, infants who died before 36 weeks CGA may have a higher risk of developing BPD if they had survived until 36 weeks CGA. Hence, the potential predictive information of death should be accounted for in BPD prediction modelling. The included models also made predictions at a variety of timepoints. Therefore, a meta-analysis of the models was difficult and may limit the clinical settings in which the model can be used. It may be sensible for the performance of future prediction models to be externally validated for BPD as well as the BPD/death composite outcome at three prediction timepoints of one, seven days and 14 days of age.

These timepoints would allow timely preventative treatment or research recruitment to be targeted to high-risk infants.

Predictors

The predictors used in the model should be easily assessed routinely during daily clinical practice and not dependable on clinical practice, such as weight loss and fluid intake. Future prediction models should also be dynamic, accounting for the changing status of the infant over time and clinical trajectory.

Predictor selection based on traditional stepwise approach or univariable analysis should be avoided, especially in small datasets. Instead, predictor selection based on a priori knowledge or statistical approach not based on prior statistical tests between predictor and outcome (e.g. principal component analysis) may be better methods¹³.

Model performance

Both discrimination (C-statistics) and calibration (calibration plot or O:E ratio) performances of the prediction models need to be assessed during external validation. A model with fair to good discrimination may be poorly calibrated³¹. Hosmer-Lemeshow goodness-of-fit test alone without other calibration measures was found not to be a suitable method to assess calibration as it is sensitive to sample size¹³. The test is often non-significant (i.e. good calibration) in small datasets while usually significant (i.e. poor calibration) in large datasets. Since the

recommendation to assess calibration in the last review nearly a decade ago³¹, only two further studies^{29 30} assessed calibration using calibration plots or O:E ratios.

An impact analysis was not carried out in any of the identified prediction models to evaluate if the prediction model improved patient outcomes. Decision curve analysis⁴⁰ may be used as an initial screening method to assess the net benefit of using the prediction model before carrying out further impact analysis. Decision curve analysis can be used on the external validation dataset without further data collection.

Practicality of model

Prediction models developed should be practical and easy to use at the bedside.

Only two published models^{26 39} provided online calculators to allow easy access risk assessment.

Changes in clinical practice and rising BPD rates, potentially makes previously published models outdated affecting its predictive ability. Over half of the published models used data from babies born more than a decade ago. Hence, new models should consider a built-in feature to allow it to learn from future babies and adapt its performance to new practices.

Strength

The systematic review was carried out based on standard Cochrane methodologies as well as recent recommendations for meta-analysis of prediction models¹⁵ and risk of bias assessment¹³. There were no language nor date restrictions. The review is anticipated to guide clinicians and researchers in not only developing and/or validating BPD prediction models in very premature infants based on recommendations of the review, but also in identifying the most promising prediction model to be externally validated in their local population.

The use of recent routinely collected clinical information in our external validation study, coupled with its large population coverage, provides an accurate representation of the current neonatal practice in England and Wales. This large cohort of nearly 63,000 very preterm infants, including infants receiving both invasive and non-invasive ventilation, forms an ideal cohort to externally validate and assess BPD prediction models.

Limitation

Only six out of the 53 identified prediction models could be validated in our cohort.

Hence, the performance of the remaining models in our cohort was unclear.

However, it is crucial that future models should only use predictors that are easily assessed in clinical practice to ensure their successful clinical implementation.


Conclusion

As preterm infant survival increases, more survivors are diagnosed with BPD along with the long-term respiratory and neurological consequences. Despite almost a doubling in the number of BPD prediction models published over the last decade, most identified in our systemic review are not used in routine clinical practice. This is due to a lack of good quality external validation studies assessing their performance on the local population of interest. Furthermore, calibration of the models is often not appropriately evaluated in most of the models. Models should be externally validated with a subsequent impact analysis before being adopted in clinical practice. Decision curve analysis may be a good screening tool to assess the net benefit of the tool prior to impact analysis.

Our systematic review has also made recommendations for future BPD prediction models including consideration of additional predictors, a more dynamic model accounting for changes in the infant's condition over time and their trajectory, and the ability to adapt performance with evolving clinical practice. A good quality, well-validated BPD prediction tool is needed to provide personalised preventative treatment and allow targeted trial recruitment to reduce the long-term impact in this vulnerable and expanding population.

Acknowledgement

We would like to thank Prof Valenzuela–Stutman in providing the algorithm for the Valenzuela–Stutman models²⁵. We are grateful to all the families that agreed to include their baby's data in the NNRD, the health professionals from the UK



Funding statement

This research received no specific funding.

Competing interest statements

None declared.

Full references

- 1. Lui K, Lee SK, Kusuda S, et al. Trends in Outcomes for Neonates Born Very Preterm and Very Low Birth Weight in 11 High-Income Countries. *J Pediatr* 2019 doi: 10.1016/j.ipeds.2019.08.020 [published Online First: 2019/10/03]
- Tan S, Szatkowski L, Moreton W, et al. Early childhood respiratory morbidity and antibiotic use in ex-preterm infants: a primary care population-based cohort study. *Eur Respir J* 2020;56(1) doi: 10.1183/13993003.00202-2020 [published Online First: 2020/07/30]
- 3. Thebaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. *Nature Reviews Disease Primers* 2019;5:23. doi: 10.1038/s41572-019-0127-7
- 4. Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. *Seminars in Perinatology* 2018;42(7):478-84. doi: 10.1053/j.semperi.2018.09.013
- 5. Gough A, Linden M, Spence D, et al. Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. *Eur Respir J* 2014;43(3):808-16. doi: 10.1183/09031936.00039513 [published Online First: 2013/07/30]
- Doyle LW, Cheong JL, Hay S, et al. Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2021;10:CD001146. doi: 10.1002/14651858.CD001146.pub6 [published Online First: 20211021]
- 7. Doyle LW, Cheong JL, Hay S, et al. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2021;11:CD001145. doi: 10.1002/14651858.CD001145.pub5 [published Online First: 20211111]
- Doyle LW, Halliday HL, Ehrenkranz RA, et al. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. *Journal of Pediatrics* 2014;165(6):1258-60. doi: https://dx.doi.org/10.1016/j.jpeds.2014.07.049
- Kwok T, Sharkey D. Systematic review of prognostic models for predicting bronchopulmonary dysplasia in very preterm infants. PROSPERO 2020 CRD42020205215 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020205215.
- 10. Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. *J Pediatr* 2018;197:300-08. doi: 10.1016/j.jpeds.2018.01.043 [published Online First: 2018/03/16]
- 11. Cochrane Neonatal. Resource for Review Authors 2020. https://neonatal.cochrane.org/resources-review-authors (accessed 19/08/2020).
- 12. Geersing GJ, Bouwmeester W, Zuithoff P, et al. Search Filters for Finding Prognostic and Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. *Plos One* 2012;7(2) doi: 10.1371/journal.pone.0032844
- 13. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Annals of Internal Medicine* 2019;170(1):51-+. doi: 10.7326/m18-1376
- Kohl C, McIntosh EJ, Unger S, et al. Online tools supporting the conduct and reporting of systematic reviews and systematic maps: a case study on CADIMA and review of existing tools. *Environmental Evidence* 2018;7(1):8. doi: 10.1186/s13750-018-0115-5

- Debray TPA, Damen J, Snell KIE, et al. A guide to systematic review and metaanalysis of prediction model performance. *Bmj-British Medical Journal* 2017;356 doi: 10.1136/bmj.i6460
- 16. Debray T, de Jong V. Metamisc: Diagnostic and Prognostic Meta-Analysis. 2019. https://CRAN.R-project.org/package=metamisc (accessed 19/08/2020). [
- 17. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software* 2010;36(3):1-48. doi: https://doi.org/10.18637/jss.v036.i03
- 18. Riley RD, Ensor J, Snell KI, et al. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. *BMJ* 2016;353:i3140. doi: 10.1136/bmj.i3140 [published Online First: 2016/06/22]
- 19. Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst Rev* 2013;2:71. doi: 10.1186/2046-4053-2-71 [published Online First: 2013/09/05]
- 20. Gale C, Morris I, Board NDAUNS. The UK National Neonatal Research Database: using neonatal data for research, quality improvement and more. *Arch Dis Child Educ Pract Ed* 2016;101(4):216-8. doi: 10.1136/archdischild-2015-309928 [published Online First: 2016/03/11]
- 21. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;338:b2393. doi: 10.1136/bmj.b2393 [published Online First: 2009/06/29]
- Cools F, Askie LM, Offringa M. Elective high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome: An individual patient data meta-analysis. *BMC Pediatrics* 2009;9:33. doi: http://dx.doi.org/10.1186/1471-2431-9-33
- 23. The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. The International Neonatal Network. *Lancet* 1993;342(8865):193-8.
- Parry G, Tucker J, Tarnow-Mordi W, et al. CRIB II: an update of the clinical risk index for babies score. *Lancet* 2003;361(9371):1789-91. doi: 10.1016/S0140-6736(03)13397-1
- 25. Valenzuela-Stutman D, Marshall G, Tapia JL, et al. Bronchopulmonary dysplasia: risk prediction models for very-low- birth-weight infants. *J Perinatol* 2019;39(9):1275-81. doi: 10.1038/s41372-019-0430-x [published Online First: 2019/07/25]
- Laughon MM, Langer JC, Bose CL, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. *American Journal of Respiratory & Critical Care Medicine* 2011;183(12):1715-22. doi: https://dx.doi.org/10.1164/rccm.201101-0055OC
- 27. Rozycki HJ, Narla L. Early versus late identification of infants at high risk of developing moderate to severe bronchopulmonary dysplasia. *Pediatric Pulmonology* 1996;21(6):345-52.
- 28. Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. *Pediatrics* 1992;90(5):663-8.
- 29. Rysavy MA, Li L, Tyson JE, et al. Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development

- Neonatal Research Network Randomized Trial. *Journal of Pediatrics* 2021 doi: 10.1016/j.jpeds.2021.05.022
- 30. Baker EK, Davis PG. Bronchopulmonary Dysplasia Outcome Estimator in Current Neonatal Practice. *Acta Paediatr* 2020 doi: 10.1111/apa.15427 [published Online First: 2020/06/21]
- 31. Onland W, Debray TP, Laughon MM, et al. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. *BMC Pediatr* 2013;13:207. doi: 10.1186/1471-2431-13-207 [published Online First: 2013/12/17]
- 32. Palta M, Gabbert D, Fryback D, et al. Development and validation of an index for scoring baseline respiratory disease in the very low birth weight neonate. *Pediatrics* 1990;86(5):714-21.
- 33. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. *Pediatrics* 1990;86(5):728-36.
- 34. Ryan SW, Nycyk J, Shaw BN. Prediction of chronic neonatal lung disease on day 4 of life. *European Journal of Pediatrics* 1996;155(8):668-71.
- 35. Kim YD, Kim EA, Kim KS, et al. Scoring method for early prediction of neonatal chronic lung disease using modified respiratory parameters. *Journal of Korean Medical Science* 2005;20(3):397-401.
- Baud O, Laughon M, Lehert P. Survival without Bronchopulmonary Dysplasia of Extremely Preterm Infants: A Predictive Model at Birth. *Neonatology* 2021:1-9. doi: https://dx.doi.org/10.1159/000515898
- 37. Henderson-Smart DJ, Hutchinson JL, Donoghue DA, et al. Prenatal predictors of chronic lung disease in very preterm infants. *Archives of Disease in Childhood -- Fetal & Neonatal Edition* 2006;91(1):F40-5.
- 38. Shim SY, Yun JY, Cho SJ, et al. The Prediction of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants through Clinical Indicators within 1 Hour of Delivery. *Journal of Korean Medical Science* 2021;36(11):12. doi: 10.3346/jkms.2021.36.e81
- 39. Ushida T, Moriyama Y, Nakatochi M, et al. Antenatal prediction models for shortand medium-term outcomes in preterm infants. *Acta obstetricia et gynecologica Scandinavica* 2021 doi: 10.1111/aogs.14136
- Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;26(6):565-74. doi: 10.1177/0272989X06295361






Figure 1: Flow diagram of literature search and included studies.

Figure 2: Summary of risk of bias assessments for included studies based on the PROBAST tool¹³.

Discrimation (C-statistics)



Calibration (O:E ratio)



Calibration plot




Figure 3: Discrimination (C-statistics) and calibration (O:E ratio and calibration plots) characteristics of prediction models externally validated using a retrospective cohort for (A) bronchopulmonary dysplasia (BPD) (n=57,572) and (B) composite BPD and death (n=62,864).